The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 multicenter investigator-initiated trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
 
David R Wise
Honoraria - OncLive
Consulting or Advisory Role - Alphasights; Foundation Medicine; Gerson Lehrman Group; Guidepoint Global; Janssen; LabCorp; Leap Therapeutics; Myovant Sciences; Pfizer; silverlight
Travel, Accommodations, Expenses - Pfizer
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche
 
Samuel R. Denmeade
Research Funding - Astellas Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed to Pfizer receive patent maintenance fees
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Alessa Therapeutics; Alessa Therapeutics; Amgen; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon; Jubilant Pharmaceuticals; Merck; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Victor Ricardo Adorno Febles
No Relationships to Disclose
 
Arjun Vasant Balar
Leadership - GT Biopharma
Stock and Other Ownership Interests - GT Biopharma
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Seagen
 
Minas P. Economides
No Relationships to Disclose
 
Cynthia A. Sirard
Employment - Leap Therapeutics
Leadership - Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Patents, Royalties, Other Intellectual Property - Pending patent application;Application No. 62/260,959
Travel, Accommodations, Expenses - Leap Therapeutics
 
Andrea Troxel
No Relationships to Disclose
 
Sarah Griglun
No Relationships to Disclose
 
Dayna Leis
No Relationships to Disclose
 
Nina Yang
No Relationships to Disclose
 
Viktoriya Aranchiy
No Relationships to Disclose
 
Sabrina Machado
No Relationships to Disclose
 
Erika Waalkes
No Relationships to Disclose
 
Gabrielle Gargano
No Relationships to Disclose
 
Fang-Ming Deng
No Relationships to Disclose
 
Ezeddin Fadel
No Relationships to Disclose
 
Luis Chiriboga
No Relationships to Disclose
 
Jonathan Melamed
No Relationships to Disclose